Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (Nasdaq: VERA) announced inducement awards for two new employees on September 5, 2024. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), include:
1. A non-qualified stock option to purchase 21,750 shares of Class A common stock
2. Restricted stock units (RSUs) for 9,875 shares of Class A common stock
The stock option has an exercise price of $38.16 per share, based on Vera's closing price on September 5, 2024. It will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting November 20, 2024. Both awards are subject to continued employment and the terms of the Inducement Plan and award agreements.
Vera Therapeutics (Nasdaq: VERA) ha annunciato premi di incentivazione per due nuovi dipendenti il 5 settembre 2024. I premi, approvati dal Comitato per la Compensazione ai sensi della Regola di quotazione Nasdaq 5635(c)(4), includono:
1. Un'opzione di acquisto di azioni non qualificate per l'acquisto di 21.750 azioni di azioni ordinarie di Classe A
2. Unità azionarie vincolate (RSU) per 9.875 azioni di azioni ordinarie di Classe A
L'opzione di acquisto ha un prezzo di esercizio di $38,16 per azione, basato sul prezzo di chiusura di Vera del 5 settembre 2024. Si acquisirà nel corso di quattro anni, con il 25% che si acquisirà al primo anniversario e il resto mensilmente per 36 mesi. Le RSU si acquisiranno nel corso di quattro anni, con il 25% che si acquisirà annualmente a partire dal 20 novembre 2024. Entrambi i premi sono soggetti a un'occupazione continuativa e ai termini del Piano di Incentivazione e agli accordi di premio.
Vera Therapeutics (Nasdaq: VERA) anunció premios de inducción para dos nuevos empleados el 5 de septiembre de 2024. Los premios, aprobados por el Comité de Compensación bajo la Regla de cotización de Nasdaq 5635(c)(4), incluyen:
1. Una opción de acciones no calificadas para comprar 21,750 acciones de acciones comunes Clase A
2. Unidades de acciones restringidas (RSU) por 9,875 acciones de acciones comunes Clase A
La opción de acciones tiene un precio de ejercicio de $38.16 por acción, basado en el precio de cierre de Vera el 5 de septiembre de 2024. Se adquirirá a lo largo de cuatro años, con el 25% adquiriéndose en el primer aniversario y el resto mensualmente durante 36 meses. Las RSU se adquirirán a lo largo de cuatro años, con el 25% adquiriéndose anualmente a partir del 20 de noviembre de 2024. Ambos premios están sujetos a la continuidad del empleo y a los términos del Plan de Inducción y acuerdos de premios.
베라 테라퓨틱스(Vera Therapeutics, Nasdaq: VERA)가 2024년 9월 5일에 두 명의 신입 직원에게 유인 보상을 발표했습니다. 보상은 나스닥 상장 규정 5635(c)(4)에 따라 보상위원회에서 승인되었으며, 다음과 같습니다:
1. A클래스 보통주 21,750주를 구매할 수 있는 비자격 주식 옵션
2. A클래스 보통주 9,875주에 대한 제한 주식 단위(RSU)
주식 옵션의 행사 가격은 2024년 9월 5일 베라의 종가를 기준으로 주당 $38.16입니다. 이 옵션은 4년에 걸쳐 매입되며, 첫 번째 기념일에 25%가 매입되고 나머지는 36개월 동안 매월 매입됩니다. RSU는 4년에 걸쳐 매입되며, 2024년 11월 20일부터 매년 25%가 매입됩니다. 두 보상 모두 계속 고용되어야 하며 유인 계획 및 보상 계약의 조건에 따라야 합니다.
Vera Therapeutics (Nasdaq: VERA) a annoncé le 5 septembre 2024 des primes d'incitation pour deux nouveaux employés. Les primes, approuvées par le Comité de Rémunération conformément à la règle de cotation Nasdaq 5635(c)(4), comprennent :
1. Une option d'achat d'actions non qualifiée pour l'achat de 21 750 actions ordinaires de Classe A
2. Des unités d'actions restreintes (RSU) pour 9 875 actions ordinaires de Classe A
L'option d'achat a un prix d'exercice de 38,16 $ par action, basé sur le prix de clôture de Vera du 5 septembre 2024. Elle sera acquise sur une période de quatre ans, avec 25 % acquis à la première date anniversaire et le reste mensuellement sur 36 mois. Les RSU seront acquis sur une période de quatre ans, avec 25 % acquis annuellement à partir du 20 novembre 2024. Les deux primes sont soumises à la continuité de l'emploi et aux conditions du Plan d'Incitation et des accords de récompense.
Vera Therapeutics (Nasdaq: VERA) gab am 5. September 2024 die Gewährung von Anreizprämien für zwei neue Mitarbeiter bekannt. Die Prämien, die vom Vergütungsausschuss gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt wurden, umfassen:
1. Eine nicht qualifizierte Aktienoption zum Kauf von 21.750 Aktien der Class A Stammaktien
2. Eingeschränkte Aktieneinheiten (RSUs) für 9.875 Aktien der Class A Stammaktien
Die Aktienoption hat einen Ausübungspreis von 38,16 $ pro Aktie, basierend auf dem Schlusskurs von Vera am 5. September 2024. Sie wird über vier Jahre vesting, wobei 25% am ersten Jahrestag und der Rest monatlich über 36 Monate vesting. Die RSUs werden über vier Jahre vesting, wobei 25% jährlich ab dem 20. November 2024 vesting. Beide Auszeichnungen sind an eine fortgesetzte Beschäftigung sowie an die Bedingungen des Anreizplans und der Auszahlungsvereinbarungen gebunden.
- Vera Therapeutics is attracting new talent with stock-based compensation
- The company's stock price was $38.16 as of September 5, 2024
- None.
BRISBANE, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on September 5, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 21,750 shares of Class A common stock and restricted stock units (RSUs) for 9,875 shares of Class A common stock to two new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option granted on September 5, 2024 has an exercise price per share equal to
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Advisors
MHawtin@lifescicomms.com
FAQ
What inducement awards did Vera Therapeutics (VERA) grant on September 5, 2024?
What is the exercise price of the stock options granted by Vera Therapeutics (VERA) on September 5, 2024?
How do the stock options and RSUs vest for the new employees of Vera Therapeutics (VERA)?
